Medtronic CoreValve® System Receives FDA Approval for Transcatheter Valve-In-Valve Procedures

Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval of the CoreValve® System for valve-in-valve (VIV) procedures in patients whose surgical aortic heart valves have failed. The CoreValve System is the first transcatheter heart valve approved in the U.S. for VIV procedures in both high and extreme risk patients who have limited options or may otherwise go untreated.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news